Category

Archives

PDHK

PKM2/PDK1 dual-targeted shikonin derivatives restore the sensitivity of EGFR-mutated NSCLC cells to gefitinib by remodeling glucose metabolism

0 views | Jun 12 2023

Compound E5, a dual inhibitor of PKM2/PDK1, demonstrates potent inhibitory activity against EGFR mutant NSCLC cells, exhibits good anti-tumor efficacy in xenografted mouse models, and shows potential as an adjunct to gefitinib in the treatment of EGFR-TKI-resistant NSCLC. [Read the Full Post]